Lyka Labs Reports Net Loss of Rs 362.68 Lakhs in Q2 FY26

Lyka Labs Limited , a pharmaceutical company, has announced its financial results for the second quarter of fiscal year 2026, ending September 30, 2025. The company reported a net loss and a decline in revenue compared to the same period last year.

Financial Performance

Particulars (in lakhs)	Q2 FY26	Q2 FY25	Change (%)
Revenue from Operations	3,297.04	4,115.51	-19.89
Total Income	3,418.51	4,128.45	-17.20
Net Profit/(Loss)	(362.68)	247.29	-246.66
EPS (in Rs)	(1.02)	0.69	-247.83

Lyka Labs reported a net loss of Rs 362.68 lakhs for the quarter, compared to a profit of Rs 247.29 lakhs in the same quarter of the previous year. The company's revenue from operations declined to Rs 3,297.04 lakhs from Rs 4,115.51 lakhs year-on-year, representing a decrease of 19.89%.

Key Highlights

Expected Credit Loss Provision: The company recognized an Expected Credit Loss (ECL) provision of Rs 484.03 lakhs for international trade receivables during the quarter.
Preference Share Redemption: During the quarter, 1,08,570 preference shares worth Rs 108.57 lakhs were redeemed.
Earnings Per Share: The earnings per share (EPS) stood at negative Rs 1.02 compared to positive Rs 0.69 in the previous year's quarter.
Board Decisions: The Board of Directors approved the quarterly financial results and decided to defer the decision on shifting the registered office.

Consolidated Results

On a consolidated basis, Lyka Labs reported a net loss of Rs 321.44 lakhs for the quarter, compared to a profit of Rs 191.13 lakhs in the same period last year. The consolidated revenue from operations was Rs 3,666.05 lakhs, down from Rs 4,115.51 lakhs in Q2 FY25.

Management Commentary

Kunal Gandhi, Managing Director & CEO of Lyka Labs Limited, stated, "The company has faced challenges this quarter, reflected in our financial performance. We are actively assessing the situation and implementing measures to improve our operational efficiency and financial position."

Future Outlook

While the company has deferred the decision on shifting its registered office, it continues to evaluate strategic options for future growth. The management is focused on addressing the challenges in international trade receivables, as evidenced by the significant ECL provision made during the quarter.

Lyka Labs operates in the pharmaceutical sector, which remains a critical industry. The company's future performance will likely depend on its ability to navigate market challenges, improve revenue streams, and manage operational costs effectively.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+11.43%	+0.52%	-19.66%	-47.86%	-51.26%	+101.16%

Lyka Labs Limited , a company listed on both BSE and NSE, has reported a significant change in its promoter shareholding. Kunal Gandhi, a promoter of the company, has increased his stake through a substantial share acquisition.

Key Details of the Transaction

Aspect	Details
Acquirer	Kunal Gandhi (Promoter)
Shares Acquired	13,50,000
Stake Acquired	4.08%
Mode of Acquisition	Transmission
Previous Holder	Narendra I. Gandhi (HUF)
Transaction Date	June 27, 2023

Impact on Shareholding

Shareholder	Before Transaction	After Transaction
Kunal Gandhi	10,69,152 (3.23%)	24,19,152 (7.31%)
Promoter Group	56,97,161 (17.22%)	56,97,161 (17.22%)

Additional Information

The total promoter group holding, including persons acting in concert, remains unchanged at 17.22%.
Persons acting in concert include Nehal N. Gandhi, Enai Trading and Investment Private Limited, and Lyka Generics Limited.
Lyka Labs' total equity share capital stands at 3,30,90,000 shares.

This transaction represents a significant increase in Kunal Gandhi's individual stake in Lyka Labs, more than doubling his shareholding percentage. However, it's important to note that the overall promoter group holding has not changed as a result of this internal transfer of shares.